You are here
Clinical Trials: Heart Attack
Each Clinical Trial will open in a new browser window or tab.
Conditions: Myocardial Infarction; Myocardial Ischemia; Myocardial Stunning
Intervention: Biological: mitochondria and MSC-derived exosomes
Sponsor: Tehran University of Medical Sciences
Recruiting
Intervention: Biological: mitochondria and MSC-derived exosomes
Sponsor: Tehran University of Medical Sciences
Recruiting
Conditions: Ischemic Heart Disease; Ischemic Cardiomyopathy; Heart Failure, Systolic; Heart Failure NYHA Class III; Heart Failure NYHA Class II; Heart Failure NYHA Class IV; Coronary Artery Disease
Interventions: Procedure: Epicardial AAMs-patch transplantation; Diagnostic Test: RNA-stabilized whole blood sampling; Diagnostic Test: Plasma sampling; Diagnostic Test: Transthoracic echocardiography; Diagnostic Test: Late-gadolinium enhancement cardiac magnetic resonance imaging (LGE-CMRI); Other: Symptom-scaling; Other: 6-minute walking test (6MWT); Diagnostic Test: Blood sampling (NT-proBNP); Diagnostic Test: Transesophageal echocardiography
Sponsors: Hospital District of Helsinki and Uusimaa; University of Helsinki
Not yet recruiting
Interventions: Procedure: Epicardial AAMs-patch transplantation; Diagnostic Test: RNA-stabilized whole blood sampling; Diagnostic Test: Plasma sampling; Diagnostic Test: Transthoracic echocardiography; Diagnostic Test: Late-gadolinium enhancement cardiac magnetic resonance imaging (LGE-CMRI); Other: Symptom-scaling; Other: 6-minute walking test (6MWT); Diagnostic Test: Blood sampling (NT-proBNP); Diagnostic Test: Transesophageal echocardiography
Sponsors: Hospital District of Helsinki and Uusimaa; University of Helsinki
Not yet recruiting
Conditions: Myocardial Reperfusion Injury; Treatment Outcome; Prognosis; ST Elevation Myocardial Infarction
Intervention: Device: Extracorporeal cardiac shock wave therapy(ECSW)
Sponsor: The First Affiliated Hospital of Kunming Medical College
Not yet recruiting
Intervention: Device: Extracorporeal cardiac shock wave therapy(ECSW)
Sponsor: The First Affiliated Hospital of Kunming Medical College
Not yet recruiting
Condition: Chronic Ischemic Left Ventricular Dysfunction
Interventions: Drug: Human Embryonic Stem Cell-Derived Cardiomyocyte 50M cells; Drug: Human Embryonic Stem Cell-Derived Cardiomyocyte 150 cells; Drug: Human Embryonic Stem Cell-Derived Cardiomyocyte 300M cells
Sponsor: Joseph C. Wu
Not yet recruiting
Interventions: Drug: Human Embryonic Stem Cell-Derived Cardiomyocyte 50M cells; Drug: Human Embryonic Stem Cell-Derived Cardiomyocyte 150 cells; Drug: Human Embryonic Stem Cell-Derived Cardiomyocyte 300M cells
Sponsor: Joseph C. Wu
Not yet recruiting
Conditions: Myocardial Infarction, Acute; Myocardial Infarction First; Myocardial Infarction, Anterior Wall; Cardiac Remodeling, Ventricular; STEMI; Regenerative Medicine; Heart Failure
Interventions: Biological: Umbilical Cord-Derived Wharton's Jelly Mesenchymal Stem Cells (WJ-MSCs); Other: Conventional Treatment
Sponsors: Shiraz University of Medical Sciences; National Institute of Medical Research Development (NIMAD), Iran; Cell Tech Pharmed Company, Iran
Recruiting
Interventions: Biological: Umbilical Cord-Derived Wharton's Jelly Mesenchymal Stem Cells (WJ-MSCs); Other: Conventional Treatment
Sponsors: Shiraz University of Medical Sciences; National Institute of Medical Research Development (NIMAD), Iran; Cell Tech Pharmed Company, Iran
Recruiting
Conditions: Myocardial Ischemia; Ventricular Dysfunction, Left
Intervention: Biological: Allogeneic Human Umbilical Cord Mesenchymal Stem Cells
Sponsor: Shanghai East Hospital
Recruiting
Intervention: Biological: Allogeneic Human Umbilical Cord Mesenchymal Stem Cells
Sponsor: Shanghai East Hospital
Recruiting
Conditions: Diabetes Mellitus; Ischemic Heart Disease
Interventions: Drug: 100 million Allogeneic Mesenchymal Human Stem Cells; Other: Placebo
Sponsors: Joshua M Hare; National Heart, Lung, and Blood Institute (NHLBI)
Not yet recruiting
Interventions: Drug: 100 million Allogeneic Mesenchymal Human Stem Cells; Other: Placebo
Sponsors: Joshua M Hare; National Heart, Lung, and Blood Institute (NHLBI)
Not yet recruiting
Conditions: Myocardial Infarction; Heart Diseases
Intervention: Device: Heart patch seeded with autologous cardiomyocytes and amnion epithelial stem cells
Sponsor: Rumah Sakit Pusat Angkatan Darat Gatot Soebroto
Not yet recruiting
Intervention: Device: Heart patch seeded with autologous cardiomyocytes and amnion epithelial stem cells
Sponsor: Rumah Sakit Pusat Angkatan Darat Gatot Soebroto
Not yet recruiting
Condition: Coronary Artery Disease
Intervention: Biological: Intravenous infusion human umbilical Wharton's jelly-derived mesenchymal stem Cell or placebo PBS
Sponsors: Navy General Hospital, Beijing; Chinese PLA General Hospital; Peking University Third Hospital; Peking Union Medical College Hospital; Xijing Hospital
Not yet recruiting
Intervention: Biological: Intravenous infusion human umbilical Wharton's jelly-derived mesenchymal stem Cell or placebo PBS
Sponsors: Navy General Hospital, Beijing; Chinese PLA General Hospital; Peking University Third Hospital; Peking Union Medical College Hospital; Xijing Hospital
Not yet recruiting
Condition: Acute Myocardial Infarction
Interventions: Biological: Intravenous infusion placebo; Biological: Intravenous infusion WJMSCs
Sponsors: Navy General Hospital, Beijing; Peking University Third Hospital; Peking Union Medical College Hospital; Xijing Hospital; Chinese PLA General Hospital
Not yet recruiting
Interventions: Biological: Intravenous infusion placebo; Biological: Intravenous infusion WJMSCs
Sponsors: Navy General Hospital, Beijing; Peking University Third Hospital; Peking Union Medical College Hospital; Xijing Hospital; Chinese PLA General Hospital
Not yet recruiting
2023 AlphaMed Press ©